Tryptophan Metabolism in Kidney Disease

NCT ID: NCT00758537

Last Updated: 2009-07-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-01-31

Study Completion Date

2008-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Tryptophan metabolism in kidney disease will be investigated in patients with chronic kidney disease stages (ADOQI 3-5). Tryptophan levels and respective catabolites will be assessed under hemodialysis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with chronic kidney disease stage 3

No interventions assigned to this group

patients with chronic kidney disease stage 4

No interventions assigned to this group

patients with chronic kidney disease stage 5 (ESRD)

No interventions assigned to this group

Controls (no kidney disease)

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Chronic kidney disease (for \> 3months) stages (National Kidney foundation/ADOQI): 3-5

Exclusion Criteria

* Signs of infection or systemic inflammation
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Charite University, Berlin, Germany

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Charite UNiversity Medicine Berlin, Germany

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Petra Reinke, Md PhD

Role: PRINCIPAL_INVESTIGATOR

Charite University Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Charite University Medicine Berlin

Berlin, State of Berlin, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TRY1STU

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Chronic Kidney Disease Screening
NCT07153432 RECRUITING
The CPH-MBD Cohort
NCT07193056 NOT_YET_RECRUITING